Patisiran is beneficial for the treatment of TTR cardiac amyloidosis
Crossref DOI link: https://doi.org/10.1038/s41569-023-00955-2
Published Online: 2023-11-06
Published Print: 2024-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Fernández-Ruiz, Irene
Text and Data Mining valid from 2023-11-06
Version of Record valid from 2023-11-06
Article History
First Online: 6 November 2023